StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of NASDAQ:TTNP opened at $3.40 on Monday. The business has a fifty day moving average of $3.54 and a 200-day moving average of $4.71. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- What Are Earnings Reports?
- Oracle Announces Game-Changing News for the AI Industry
- Top Biotech Stocks: Exploring Innovation Opportunities
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Calculate Return on Investment (ROI)
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
